EN DE
Watch Nautilus Biotechnology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nautilus Biotechnology Inc (NAUT) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Nautilus Biotechnology Inc stock $1.13, price $2.10, that is 46.2% below the price, quality 49 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US63909J1088

NB Nautilus Biotechnology Inc logo Thin data Nov 17, 2026

Nautilus Biotechnology Inc

NAUT · US

Far too expensive (fair value 46% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Recent news mostly positive 
Quality 49/100 
Fair value $1.13 · Strongly overvalued 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Nautilus Biotechnology Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.00 $0.6390 Fair Value $1.13 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.6390 – $8.00 · fair‑value band $0.8500 – $1.42 · the $2.10 price screens above the $1.13 fair value. As of Nov 17, 2026.

Follow Nautilus Biotechnology in your weekly email

Every Wednesday you see whether Nautilus Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.

Show moreShow less

The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.

It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.

In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs.

It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Stock analysis

Nautilus Biotechnology Inc (NAUT) currently trades at $2.10, while our estimate is $1.13, 46% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.8500 (bear) to $1.42 (bull), the price of $2.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Nautilus Biotechnology Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$59.0M in FY2025.

Key figures

Market cap $267M Micro · EPS (TTM) $−0.4600 · Return on equity −41.0% · Return on assets (EBIT) −24.9% (5-year average) · Operating margin −7,153% · Revenue (TTM) $424K · Free cash flow −$52.0M · Net debt $17.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 146% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −46%, NAUT screens richer than that median.

Fair Value

Bear $0.8500 Fair Value $1.13 Bull $1.42
Price $2.10 · Downside -46.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 56
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 43
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleAH Bio Fund II, L.P.10% owner5,000,000 shares at $2.35$11.8MJun 2, 2026
  • BuySujal M PatelCEO, President, and Secretary, Director, 10% owner25,000 shares at $2.61$65,250Mar 4, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NAUT screens overvalued: fair value 46% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (75 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Nautilus Biotechnology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −46.2% · Bottom 25%
Profitability
Return on assets −30.9% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.70× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs NAUT
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs NAUT
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs NAUT
argenx SE ARGX $950.95 $908.40 −4% vs NAUT
CSL Limited CSL A$199.55 A$186.49 −7% vs NAUT
Moderna, Inc MRNA $215.27 $135.64 −37% vs NAUT
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs NAUT
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs NAUT
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs NAUT
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs NAUT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nautilus Biotechnology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nautilus Biotechnology Inc Fair Value". https://www.fairvalue-calculator.com/stock/NAUT

Frequently asked questions

Is Nautilus Biotechnology Inc (NAUT) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $1.13 versus a price of $2.10, about 46% lower (overvalued).
What is the fair value of NAUT?
Our estimate for Nautilus Biotechnology Inc is $1.13 (as of Nov 17, 2026), built from audited fundamentals. The current price: $2.10.
What is the quality score of NAUT?
Nautilus Biotechnology Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nautilus Biotechnology Inc (NAUT)?
Our calculated price target is the estimate of $1.13 (as of Nov 17, 2026). Cautious scenario $0.8500, optimistic scenario $1.42. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Nautilus Biotechnology Inc stock forecast for 2026?
Our estimate puts fair value at $1.13, about 46% lower versus a price of $2.10 (overvalued). Cautious scenario $0.8500, optimistic scenario $1.42. The calculation is refreshed regularly with new filings.
What is the revenue of Nautilus Biotechnology Inc (NAUT)?
Nautilus Biotechnology Inc reported trailing-twelve-month revenue of about $424K (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Nautilus Biotechnology Inc (NAUT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nautilus Biotechnology Inc it is $1.13 per share (as of Nov 17, 2026), against a price of $2.10.
Is Nautilus Biotechnology Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, NAUT trades above its calculated fair value: price $2.10, fair value $1.13, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NAUT?
No. The price is what the market pays today ($2.10); the fair value is what the company's own numbers justify ($1.13). For Nautilus Biotechnology Inc the two are $0.9700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nautilus Biotechnology Inc worth?
The market values Nautilus Biotechnology Inc at about $267M (market capitalisation, as of Nov 17, 2026). Per share that is $2.10; our models calculate a fair value of $1.13 per share.
What do the bullish and bearish scenarios say about NAUT?
Our models span a range for Nautilus Biotechnology Inc: cautious scenario $0.8500, base $1.13, optimistic $1.42 per share (as of Nov 17, 2026, price $2.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nautilus Biotechnology Inc (NAUT)?
Balance-sheet figures for Nautilus Biotechnology Inc (as of Nov 17, 2026): return on equity −41.0%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is NAUT from its 52-week high?
Nautilus Biotechnology Inc trades at $2.10, about 47% below its 52-week high of $3.95 and 146% above the low of $0.8520 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.13 is for.
Which stocks are comparable to Nautilus Biotechnology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nautilus Biotechnology Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $2.10, calculated fair value $1.13 (−46%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Nautilus Biotechnology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nautilus Biotechnology Inc (NAUT)?
The closing price on Nov 16, 2026 was $2.10. Our estimate is $1.13, about 46% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nautilus Biotechnology Inc right now?
The price sits above even our optimistic bull case ($1.42). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Nautilus Biotechnology Inc

How large is the market capitalisation of Nautilus Biotechnology Inc (NAUT)?
The market capitalisation of Nautilus Biotechnology Inc is $267M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Nautilus Biotechnology Inc (NAUT)?
Earnings per share at Nautilus Biotechnology Inc are $−0.4600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nautilus Biotechnology Inc (NAUT)?
The return on equity (ROE) of Nautilus Biotechnology Inc is −41.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nautilus Biotechnology Inc (NAUT)?
On an EBIT basis the return on assets of Nautilus Biotechnology Inc is −24.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nautilus Biotechnology Inc (NAUT)?
The operating margin of Nautilus Biotechnology Inc is −7,153% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Nautilus Biotechnology Inc (NAUT) generate?
The free cash flow of Nautilus Biotechnology Inc is −$52.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nautilus Biotechnology Inc (NAUT) carry?
The net debt of Nautilus Biotechnology Inc is $17.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nautilus Biotechnology Inc in the live analysis

One click puts Nautilus Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.